Revenue
15.6 million USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 15603000 USD Source
Fundies. English
Pelthos Therapeutics Inc.
EDGARAnnual consolidated revenue for 2025: about USD 16.8M, using the latest reported figures. The previous period, 2024, was about USD 0.
Latest quarter
Operating margin
-111.02%
2026 Q2 · %
Operating cash flow
-7.66 million USD
2026 Q2 · USD
Free cash flow
-7.67 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 24.2 million USD Source
Exact value
24192000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 3.72 million shares Source
Exact value
3718624 shares
Reported share-count change
452.28% · 3.05 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
43.3 million USD
2025-07-01 – 2026-06-30
Net income
-86.4 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2025-12-31
- Operating income: 4 of 11 periods available· newest 2025-12-31
- Net income: 4 of 11 periods available· newest 2025-12-31
- Operating cash flow: 4 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2025-12-31
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 2 of 11 periods available· newest 2025-12-31
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+USD 16.8 millionPrior period
USD 0
–
Current period
USD 16.8 million
–
Exact inputs and evidence
16795000 − 0 = 16795000 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source16795000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 35.36 millionPrior period
−USD 7.96 million
–
Current period
−USD 43.32 million
–
Exact inputs and evidence
-43319000 − -7955000 = -35364000 USD
-7955000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-43319000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 16.8 millionPrior period
−USD 5.79 million
–
Current period
−USD 22.59 million
–
Exact inputs and evidence
-22590000 − -5792000 = -16798000 USD
-5792000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-22590000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 99,000Prior period
USD 0
–
Current period
USD 99,000
–
Exact inputs and evidence
99000 − 0 = 99000 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source99000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 16.8 million 100% of revenue
- Cost of revenue USD 3.99 million 24% of revenue
- Operating expenses USD 43.68 million 260% of revenue
- Other operating costs Derived USD 1.56 million 9.3% of revenue
- Operating income −USD 32.43 million −193% of revenue
- Tax, interest and other Derived USD 10.89 million 65% of revenue
- Net income −USD 43.32 million −258% of revenue
Cash
- Operating cash flow −USD 22.59 million −135% of revenue
- Capital expenditure USD 99,000 0.6% of revenue
- Free cash flow Derived −USD 22.69 million −135% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2024 Not shown: operating income or net income is not reported.
- 2025 Operating loss: operating costs were 293% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 0 | 7571000 Derived | -7571000 | 384000 Derived | -7955000 | -5792000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 16795000 | 49225000 Derived | -32430000 | 10889000 Derived | -43319000 | -22689000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 16.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 0 |
|
| 2025 | Revenue | 16795000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -193.1% 2025
Net margin -257.9% 2025
Free cash flow margin -135.1% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | Not reported |
|
| 2025 | Operating margin | -193.1% |
|
| 2024 | Net margin | Not reported |
|
| 2025 | Net margin | -257.9% |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | -135.1% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -22.6M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | -5792000 |
|
| 2025 | Operating cash flow | -22590000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -22.7M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | -5792000 |
|
| 2025 | Free cash flow | -22689000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
70.2% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Liabilities / assets | 298.2% |
|
| 2025 | Liabilities / assets | 70.2% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.05× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Current assets / current liabilities | 0.34× |
|
| 2025 | Current assets / current liabilities | 2.05× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | −USD 2.46 million Exact valueExact value: -2458589 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.57 million Exact valueExact value: -1567149 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 7.38 million Exact valueExact value: -7380793 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 981,031 Exact valueExact value: -981031 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 7.96 million Exact valueExact value: -7955000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.79 million Exact valueExact value: -5792000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.79 million Calculation and evidence-5792000 − 0 USD Exact free cash flow: -5792000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 43.32 million Exact valueExact value: -43319000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 22.59 million Exact valueExact value: -22590000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 99,000 Exact valueExact value: 99000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 22.69 million Calculation and evidence-22590000 − 99000 USD Exact free cash flow: -22689000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
36 filings · 841 latest values · 841 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001919246, 1919246, CHRO, PTHS, edgar:1919246
Also known as Channel Therapeutics Corp, Channel Therapeutics Corporation, Chromocell Therapeutics Corp, Chromocell Therapeutics Corporation, Pelthos Therapeutics Inc.